Abstract
This review examines pharmacotherapy of rhythm management for atrial fibrillation (AF) in the elderly. There is little research specifically focused on this topic in the elderly but five of the seven randomized controlled trials comparing pharmacologic rate control to pharmacologic rhythm control enrolled patients who can be considered “elderly”. Collectively, these studies showed that the rate control approach was favored for the outcomes of mortality, hospitalization and cost. With respect to stroke and systemic thromboembolism, no clear advantage accrues to either approach and the major therapeutic intervention for stroke prevention is anticoagulation. Rhythm control may be better for relief of symptoms in those who are highly symptomatic but symptoms are usually less problematic in the elderly. Little comparative information is available about use of specific drugs in the elderly but beta blockers are probably the preferred initial therapy for rate control when possible. Although amiodarone is the most effective rhythm control agent, its adverse effect profile suggests it should be reserved for use when other antiarrhythmic drugs fail or are contraindicated. To date, “upstream” or preventive therapies have not been specifically evaluated in the elderly but nebivolol (a beta blocker) does not prevent emergence of AF in elderly patients with heart failure, although it does provide the other salutary benefits of beta blocker therapy seen in younger heart failure patients.
Similar content being viewed by others
References
Miyasaka, Y., Barnes, M. E., Gersh, B. J., Cha, S. S., Bailey, K. R., Abhayaratna, W. P. S., et al. (2006). Secular trends in incidence of atrial fibrillation in Olmstead County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation, 114, 119–125.
Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., et al. (2006). ACC/AHA/ESC 2006 guidelines for management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for Management of Patients with Atrial Fibrillation). Journal of the American College of Cardiology, 48, e149–e246.
Kopecky, S. L., Gersh, B. J., McGoon, M. D., Chu, C. P., Ilstrup, D. M., Chesebro, J. H., et al. (1999). Lone atrial fibrillation in elderly patients: a marker for cardiovascular risk. Archives of Internal Medicine, 159, 1118–1122.
Levy, S., Maarek, M., Coumel, P., Guize, L., Lekiiffre, J., Medvedowsky, J. L., et al. (1999). Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. Circulation, 99, 3028–3035.
Wyse, D. G. (2005). Rate control vs. rhythm control strategies in atrial fibrillation. Progress in Cardiovascular Diseases, 48, 125–138.
AF-CHF Investigators (2002). Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. American Heart Journal, 144, 597–607.
Yamashita, T., Ogawa, S., Aizawa, Y., Atarashi, H., Inoue, H., Ohe, T., et al. (2003). Investigation of the optimal treatment strategy for atrial fibrillation in Japan. The J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation) study design. Circulation Journal, 67, 738–741.
Wyse, D. G., Waldo, A. L., DiMarco, J. P., Domanski, M. J., Rosenberg, Y., Schron, E. B., et al. (2002). A comparison of rate control and rhythm control in patients with atrial fibrillation. The New England Journal of Medicine, 347, 1825–1833.
Steinberg, J. S., Sadaniantz, A., Kron, J., Krahn, A., Denny, D. M., Daubert, J., et al. (2004). Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation, 109, 1973–1980.
Olshansky, B., Sami, M., Rubin, A., Kostis, J., Shorofsky, S., Slee, A., et al. (2005). Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study. The American Journal of Cardiology, 95, 404–405.
Akiyama, T., Pawitan, Y., Campbell, W. B., Papa, L., Barker, A. H., Rubbert, P., et al. (1992). Effects of advancing age on efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. Journal of the American Geriatrics Society, 40, 666–672.
Bauer, L. A., Black, D., Gensler, A., & Sprinkle, A. (1989). Influence of age, renal function and heart failure on procainamide clearance and n-acetylprocainamide serum concentrations. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 27, 213–216.
Sherman, D. G., Kim, S. G., Boop, B. S., Corley, S. D., DiMarco, J. P., Hart, R. G., et al. (2005). Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Archives of Internal Medicine, 165, 1185–1191.
Mant, J., Hobbs, R., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y. H., et al. (2007). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study): a randomized controlled trial. Lancet, 370, 493–503.
Hylek, E. M., Evans-Molina, C., Shea, C., Henault, H. E., & Regan, S. (2007). Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation, 115, 2689–2696.
Jenkins, L. S., Brodsky, M., Schron, E., Chung, M., Rocco, T., Lader, E., et al. (2005). Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. American Heart Journal, 149, 112–120.
Chung, M. K., Shemanski, L., Sherman, D. G., Greene, H. L., Hogan, D. B., Kellen, J. C., et al. (2005). Functional status in rate- vs. rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) functional status substudy. Journal of the American College of Cardiology, 46, 1891–1899.
Marshall, D. A., Levy, A. R., Vidaillet, H., Fenwick, E., Slee, A., Blackhouse, G., et al. (2004). Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Annals of Internal Medicine, 141, 653–661.
Van Gelder, I. C., Wyse, D. G., Chandler, M. L., Cooper, H. A., Olshansky, B., Hagens, V. E., et al. (2006). Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace, 8, 935–942.
The AFFIRM First Antiarrhythmic Drug Substudy Investigators (2003). Maintenance of sinus rhythm in patients with atrial fibrillation. An AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology, 42, 20–29.
Olshansky, B., Rosenfeld, L. E., Warner, A. L., Solomon, A. J., O’Neill, G., Sharma, A., et al. (2004). AFFIRM Investigators. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to rate control in atrial fibrillation. Journal of the American College of Cardiology, 43, 1201–1208.
Wyse, D. G., & Gersh, B. J. (2004). Atrial fibrillation: a perspective: thinking inside and outside the box. Circulation, 109, 3089–3095.
Engelmann, M. D., & Svendsen, J. H. (2005). Inflammation in the genesis and perpetuation of atrial fibrillation. European Heart Journal, 26, 2083–2092.
McMurray, J., Kober, L., Robertson, M., Dargie, H., Colucci, W., Lopez-Sendon, J., et al. (2005). Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-infarction Survival in Control in Left Ventricular Dysfunction (CAPRICORN) trial. Journal of the American College of Cardiology, 45, 525–530.
Nasr, I. A., Bouzamondo, A., Hulot, J. S., Dubourg, O., Le Heuzey, J. Y., & Lechat, P. (2007). Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. European Heart Journal, 28, 457–462.
Flather, M. D., Shibata, M. C., Coats, A. J., Van Velhuisen, D. J., Parkhomenko, A., Borbola, J., et al. (2005). SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal, 26, 215–225.
Conflict of Interest and Disclosures
For past 2 years: Research Grants—Cardiome/Astellas, Medtronic; Scientific Advisory Board—Boerhinger Ingelheim, Cardiome/Astellas, CV Therapeutics, Medtronic, Novartis, Sanofi Aventis, Transoma, Bristol Myers Squibb; Speaker—Cardiome/Astellas, Eisai Pharma; All <$10,000.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wyse, D.G. Pharmacotherapy for rhythm management in elderly patients with atrial fibrillation. J Interv Card Electrophysiol 25, 25–29 (2009). https://doi.org/10.1007/s10840-008-9329-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10840-008-9329-8